Document is current
Any future updates will be listed below
-
Authors
Merz, Maximilian https://orcid.org/0000-0002-2805-5973
Jurgens, Eric
Fandrei, David
Usmani, Saad Z. https://orcid.org/0000-0002-5484-8731
Mailankody, Sham https://orcid.org/0000-0002-2815-9561
-
Funding
Funding for this research was provided by:
European Commission (CERTAINTY)
- License Information
-
More Information
Article History
Received: 8 January 2026
Revised: 29 January 2026
Accepted: 10 March 2026
First Online: 31 March 2026
Competing interests
: M.M. is supported by research grants from the Jose Carreras Leukemia Foundation, the International Myeloma Society and the Hector Foundation as well as European Union project CERTAINTY. MM is on advisory boards, and receives honoraria and research support for/from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, SpringWorks, Sanofi, Takeda. S.Z.U. Grants and personal fees: AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Merck, Mundipharma, Oncopeptides, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda. S.M. Consultancy: Evicore, Optum, BioAscend, Janssen Oncology, BMS, AbbVie, HMP Education, and Legend Biotech; Honoraria: OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications. Research funding: Janssen Oncology, BMS, Allogene Therapeutics, Fate Therapeutics, Caribou Therapeutics, and Takeda Oncology.
